MET Inhibitor Sensitivity Evaluation Kit
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Patients with tumors caused by MET gene abnormalities have varying sensitivities to MET inhibitors, making it challenging to achieve effective treatment as current methods lack a standardized approach for screening sensitivity.
Innovation Solution
A kit and system for evaluating patient sensitivity to MET inhibitors, including primer pairs and probes specific to nucleotide sequences and antibodies, which detect specific sequences or amino acid sequences associated with MET gene deletions, enabling the determination of patient sensitivity through amplification, sequencing, and computational analysis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If MET inhibitors are used to treat tumors caused by MET gene abnormality, then treatment effectiveness is improved, but patient sensitivity varies making it difficult to identify suitable patients
Solution Approach 1:
The patent applies preliminary action by performing sensitivity evaluation before treatment. The kit detects specific nucleotide sequences (SEQ ID NO: 1, 4) and amino acid sequences (SEQ ID NO: 13, 16) associated with MET gene abnormalities in advance, allowing clinicians to identify suitable patients before administering MET inhibitors, thereby ensuring treatment effectiveness while accounting for patient sensitivity variations
2Measurement precision
If standardized screening methods are implemented to identify sensitive patients, then treatment precision is improved, but current methods lack standardization
Solution Approach 1:
The patent applies segmentation by dividing the sensitivity evaluation into distinct detectable components: specific nucleotide sequences (SEQ ID NO: 1, 4) and amino acid sequences (SEQ ID NO: 13, 16). The kit includes specialized reagents for detecting each sequence type, allowing precise, standardized measurement of patient sensitivity through multiple independent detection targets rather than a single complex method
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables quick identification of patients sensitive to MET inhibitors, allowing for targeted and effective treatment by detecting specific MET gene deletions in tumor cells, thereby improving treatment outcomes.
Implementation Method 1
a first primer pair capable of specifically amplifying a first nucleotide sequence
Implementation Method 2
a first probe capable of specifically binding to the first nucleotide sequence
Implementation Method 3
a first antibody for resisting a first amino acid sequence
Data Source
AI summary
A kit for evaluating the sensitivity of a patient to an MET inhibitor is provided. The kit includes a first primer pair capable of specifically amplifying a first nucleotide sequence, and/or a first probe capable of being specifically bonded to the first nucleotide sequence, wherein the first nucleotide sequence is as shown in SEQ ID NO: 1, and/or the kit comprises a second primer pair capable of specifically amplifying a second nucleotide sequence, and/or a second probe capable of being specifically bonded to the second nucleotide sequence, wherein the second nucleotide sequence is as shown in SEQ ID NO: 4. The kit provided is capable of screening the patients sensitive to an MET inhibitor.